Description: |
Valproic acid may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether valproic acid is more effective than observation in treating patients with prostate cancer. This randomized phase II trial is studying how well valproic acid works in treating patients with progressive, non-metastatic prostate cancer. The primary outcome measure is the percentage of patients exhibiting observed or predicted prostate-specific antigen (PSA) doubling time > 10 months after initiation of the study. Eligibility includes patients post definitive local therapy, with asymptomatic, non-metastatic disease, and biochemical progression (3 rising PSA values, at least 4 weeks apart, and last value greater than 1.0 ng/ml). |
Link: |
|
Site: |
JHMI |
Principal Investigator: |
Rodriguez |